{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:32:31Z","timestamp":1762918351571},"reference-count":27,"publisher":"Korean Cancer Association","issue":"2","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HA17C0055","1720150"],"award-info":[{"award-number":["HA17C0055","1720150"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2023,4,15]]},"abstract":"<jats:p>Purpose This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.Materials and Methods Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient\u2019s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg\/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.Results A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2\u2013positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).Conclusion This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.<\/jats:p>","DOI":"10.4143\/crt.2022.1360","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:42:57Z","timestamp":1667868177000},"page":"523-530","update-policy":"http:\/\/dx.doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)"],"prefix":"10.4143","volume":"55","author":[{"given":"Dae-Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Young","family":"Ock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae-Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hyuck","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Cheol","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21583"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.56.7479"},{"key":"ref4","first-page":"2602","volume-title":"Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats","author":"Shirasaka","year":"1996"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/bf02968301"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00411-8"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01531-6"},{"key":"ref8","first-page":"539","volume-title":"A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer","author":"Saeki","year":"2004"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082798"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx122"},{"key":"ref11","first-page":"5970","volume-title":"In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin","author":"Pendyala","year":"1993"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008213732429"},{"key":"ref13","first-page":"4","volume-title":"Oxaliplatin: mechanism of action and antineoplastic activity","author":"Raymond","year":"1998"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008386419047"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.16.2938"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg106"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.06.164"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg172"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-009-0758-3"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1052-3"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2489"},{"key":"ref22","first-page":"205","volume-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","author":"Therasse","year":"2000"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.24.4244"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.2.485"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.11.007"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2738-3"},{"key":"ref27","first-page":"141","volume-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer","author":"Yamada","year":"2015"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2022-1360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2022.1360","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2022-1360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T23:46:59Z","timestamp":1681343219000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2022.1360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2022.1360","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"2022-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-08","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}